Based in the ZWT Graz, EVOMEDIS was established as a spinoff from our parent company QRSKIN. The successes and experience accumulated by QRSKIN serve as a solid foundation for the development of an improved wound healing solution for the european market, being EVOSens & EVOCellic, and for its future commercialization.
about
who we are
our mission
We are a research and development stage life science company with a clear vision: to shift the current paradigm of wound management to wound healing. With our products we aim to address a high unmet need for chronic wound and deep second-degree burn patients. Globally, 11 million patients require hospitalization for their burns, while another 50 million patients suffer from chronic wounds in industrialized countries.
USA
Mexico
Germany
Austria
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
company history
2019
- Publication describing the EVOSens principle (DOI: 10.1016/ j.ejps.2021.105746)
company history
2020
- Foundation of the company
- Development of a new ex vivo burn model (DOI: 10.1016/ j.burns.2020.06.024)
- Granting of key patent in most EU countries, USA and Mexico
company history
2021
- Introduction of the freeze drying technology to human keratinocytes (DOI: 10.1016/ j.ejps.2021.105746;10.1016/ j.xphs.2021.04.018)
- Development of a new 3D In Vitro Model for Burn Wounds (DOI: 10.3390/ biomedicines9091153)
- Granting of different research funds from the FFG
- Granting of key patent in China
company history
2022
- Introduction of a porcine wound healing model (DOI: 10.3390/ biomedicines10061286)
- Granting of different research funds from the FFG an EU
- Granting of key patent in Brasil, Canda and India
company history
2023
- EVOMEDIS moved to it’s new offices at the ZWT II in Graz
- European Commission grants orphan drug designation for EVOCellic (Full press relase)
- Launching of a strategic partnership with Medical University of Graz and COREMED to foster wound healing innovation (Full press relase)
company history
2024
- Internal freeze-drying capacities set up
- Clinical study for skin tissue sampling started
- Publication of new patent WO2024104577A1 (https://patents.google.com/patent/WO2024104577A1/en)
- 2 key publications about wound healing models (https://doi.org/10.3390/biomedicines12081697) (https://doi.org/10.3390/ijms25147658)
Dr. Martin Funk
CEO, Founder
CEO, Founder
"Bring new therapies to the patients with > 25 years experience in biotech R&D"
Dr. Funk has over 25 years of experience in biotech R&D, and has been the COO of QRSKIN since 2014. He has led or owned several companies since 2011 and has management experience since 1996. In 2020 he took the lead of EVOMEDIS.
dr. ives Bernardelli de mattos
Senior Scientist
Senior Scientist
"Make wound healing the standard of care”
Dr. Bernardelli de Mattos has been working with Tissue Engineering at the University of Würzburg since 2016. His PhD Thesis was developed with a focus on wound healing process. He has six years of experience working in the wound healing field at QRSKIN GmbH.
Dr. Susrisweta Behera
Senior Scientist
Senior Scientist
"Preserve therapeutic cells for long term storage"
Dr. Susrisweta Behera completed her Ph.D. in Physical Chemistry. Her thesis focused on freezing induced acidity changes of excipients using spectroscopy techniques. At Evomedis, she applies her expertise to understand excipients behavior and optimize the stability formulations for long term storage, driving innovation in wound healing.
supervisory / advisory board
Prof. Dr. L. Kamolz
“Driving Regenerative Medicine”
Prof. Dr. L. Kamolz
“Driving Regenerative Medicine”
advisory board
Prof. Kamolz’s research specifically focuses on regenerative medicine. He studies smart and innovative wound dressings, working with in vivo skin models for burn injuries. He is also a director at COREMED, the Cooperative Centre for Regenerative Medicine. Prof. Kamolz brings highly relevant knowledge and counsel for the development of EVOMEDIS’ products.
Prof. Dr. H. Walles
“Innovating Tissue Engineering for Testing and Therapy”
Prof. Dr. H. Walles
“Innovating Tissue Engineering for Testing and Therapy”
advisory board
Prof. Walles has extensively researched tissue engineered skin tissues, with a particular focus on autologous tissues. She was chair of Tissue Engineering and Regenerative Medicine at the Medical Faculty of the University of Würzburg from 2009 to 2019. Her experience in growing human tissues is highly valuable to help setting up the manufacturing process of EVOMEDIS’ allogeneic wound healing solution.
Prof. Dr. W. Vanscheidt
“Fighting Chronic Wounds”
Prof. Dr. W. Vanscheidt
“Fighting Chronic Wounds”
advisory board
Prof. Vanscheidt is a prolific scientist in the field of dermatology and chronic wounds, with over 300 publications to his name. Beyond research, he is also heavily involved in clinical practice. He is President and Congress President of the Annual Meeting of the German Society for Wound Healing as well as Board Member of the European Wound Management Association. He thereby has a strong overview of trends in the field of wound care, which he can use to help inform EVOMEDIS in its development plans.
Erwin Feldhaus
“Shaping companies by building trust between stakeholders”
Erwin Feldhaus
“Shaping companies by building trust between stakeholders”
advisory board
Erwin Feldhaus is an entrepreneur and fractional CFO with a strong track record in guiding companies through transformation, growth, and financial complexity. Drawing on multi-sector leadership and investment experience, he helps founders, boards, and executives steer through uncertainty with a pragmatic, hands-on approach. His style combines financial and strategic rigour with a people-centred mindset, enabling teams to build resilience, clarity, and lasting value.
contact us
Lets work together,
for the better!
Dr. Martin Funk, CEO
